Background/Aims: Several recent studies have demonstrated that Stathmin 1expression may be closely associated with prognosis in patients with various types of cancers. In the present study, we conducted a meta-analysis of all available studies in the English literature to assess the prognostic value of Stathmin 1expression in patients with solid cancers. Methods: The online databases PubMed, Embase, and Web of Science were searched for literature regarding Stathmin 1 and its association with patient outcomes associated with solid cancers. Results: A total of 23 articles including 26 studies that contained 5 335 patients were retrieved and analyzed. Our results indicated that high Stathmin 1 expression yielded a worse overall survival (OS) (hazard ratio [HR] = 2.17, 95% confidence interval [CI]: 1.81-2.60), disease-free survival (DFS) (HR = 2.46, 95% CI: 2.00-3.02), disease-specific survival (DSS) (HR = 1.98, 95% CI: 1.58-2.47) and progression-free survival (PFS)/recurrence-free survival (RFS) (HR = 2.09, 95% CI: 1.51-2.89). Furthermore, the association of high Stathmin 1 expression with poor survival was significant even for sub-group analyses of different tumor types, ethnicities, methods used to calculate HRs, detected methods, and analysis types. Conclusion: In summary, this metaanalysis determined that high Stathmin 1 expression is associated with poor prognosis in patients with solid cancers and expression of this protein could be a clinically useful prognostic biomarker.
Introduction
Based on GLOBOCAN estimates, approximately 14.1 million new cancer cases and 8.2 million cancer-related deaths were reported in 2012 worldwide. The occurrence of cancer is increasing due to population growth and aging, as well as an increasing prevalence of established risk factors such as smoking, obesity, physical inactivity, and changing reproductive patterns associated with urbanization and economic development [1] . Prevention and early detection should be the mainstays of cancer control. Population screenings of asymptomatic
Quality assessment
The eligible studies included in our meta-analysis were independently assessed by two researchers according to the Newcastle-Ottawa Scale (NOS) guidelines on a rating scale from 0 (lowest) to 9 (highest) [20] . Studies with scores of 6 or more were rated as being of high quality.
Data extraction and conversion
Relevant characteristics and outcome data were extracted from the literature by two independent reviewers. The main data of articles were tabulated as follows: (1) basic characteristics: first author's last name, publication year, country, and ethnicity; (2) clinical data: tumor type, gender, case number, age, treatment, tumor stage, follow-up duration, and detected method; (3) cut-off value and high expression number; and (4) HRs for OS, DFS, DSS, PFS, RFS, as well as their 95% CIs. In cases wherein the study provided the results of univariate and multivariate analyses, we chose the latter. Any disagreement was resolved by discussion among the investigators.
Most of the eligible studies included data pertaining to HRs and 95% CIs. If the HR and 95% CI were not available, we calculated the values by using the original data provided in the paper. If only KaplanMeier curves of Stathmin 1 were available, we were able to reconstruct the HRs and 95% CIs from the data extracted from the survival plots. All the calculation methods mentioned above were previously reported by Parmar et al. [21] and Tierney et al. [22] . We also communicated with the corresponding authors of the published studies by email to request any additional data that were required for the meta-analysis.
Statistical analysis
High or positive expression of Stathmin 1 was defined according to the cut-off values provided in the analyzed articles. Pooled HRs and 95% CIs were used to analyze the association between Stathmin 1 expression and the survival of patients with solid tumors. An observed HR >1 implied a poorer prognosis in patients with high Stathmin 1 expression, while HR <1 indicated a better prognosis. We used Cochran's Q test and Higgins I-squared statistic (I 2 ) for measuring the heterogeneity of the combined HRs. If the P value was less than 0.05 and/or I 2 was larger than 50%, the heterogeneity of the combined HRs was considered statistically significant. A random-effects model (DerSimonian-Laird method) was used. In the absence of heterogeneity among the studies, a fixed-effects model (the Mantel-Haenszel method) was applied. The factors that may have led to heterogeneity were further analyzed by subgroup analysis. Publication bias was assessed using Begg's and Egger's tests. All data analyses were performed with STATA version 12.0 (Stata Corporation, College Station, TX, USA). A P value lower than 0.05 was considered statistically significant on two-sided tests.
Results

Search results
The process of searching and filtering the literature is shown in Fig. 1 . A total of 698 records were retrieved in accordance with our search method. Following the screening of the titles, abstracts, publication categories, and full text of each article, only 42 articles qualified for the present analysis. Among these, 19 articles were excluded (9 lacked important data, 4 used continuous or two cut-offs for Stathmin 1 expression, and 6 reported only odds ratios or relative risk estimates). Finally, 23 articles including 26 studies, (because 3 articles included two independent cohort studies, respectively) which involved 5335 patients, were included in the final meta-analysis [10] [11] [12] [13] [14] [15] [16] [17] [18] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] .
Study characteristics
The characteristics of the studies are presented in 
Quality assessment
According to the Newcastle-Ottawa scale, we assessed the quality of the 26 eligible studies included in our meta-analysis. The quality scores of the studies varied from 4 to 9, with a mean score of 6. A higher score was indicative of a better methodology. All 26 studies were included in the subsequent analysis.
Meta-analysis of OS
The main results of this meta-analysis are shown in Table 2 . Fourteen studies, which included 1855 patients, were analyzed in the current meta-analysis to assess the prognostic value of highly-expressed Stathmin 1 in solid tumors. As the studies evaluating OS were not of obvious statistical heterogeneity (I 2 = 18.7%, P = 0.249), we used a fixed-effects model to pool the HRs. As shown in Fig. 2A , the pooled analysis demonstrated that high Stathmin 1 expression was significantly associated with unfavorable OS (HR = 2.17, 95% CI: 1.81-2.60, P < 0.001).
In the tumor type subgroup, as only one study analyzed OS for meningioma, endometrial cancer, breast cancer, NPC, medulloblastoma, CRC, and colon cancer, respectively, we combined them with the analysis of other cancers. High Stathmin 1 expression was associated with poorer OS for OSCC (HR = 2.47, 95% CI: 1.29-4.75, P = 0.007), ovarian cancer (HR = 3.12, 95% CI: 1.84-5.28, P <0.001), ESCC (HR = 2.36, 95% CI: 1.51-3.67, P <0.001), and other cancers (HR = 1.96, 95% CI: 1.56-2.46, P < 0.001) (Fig. 3A) . Meanwhile, Stathmin 1 expression was significantly associated with worse OS in Caucasian patients (HR = 1.83, 95% CI: 1.42-2.35, P <0.001) and Asian patients (HR =2.61; 95% CI: 2.01-3.39; P < 0.001). High Stathmin 1 expression remained significantly associated with poor OS on subgroup analysis as well: HRs reported directly in text (HR = 2.10, 95% CI: 1.73-2.54, P <0.001), HRs 
Meta-analysis of DFS
Eight studies that included 855 patients provided suitable data for DFS analysis. The main results are listed in Table 3 . In the absence of heterogeneity among the studies (I 2 = 0.0%, P = 0.612), we also used a fixed-effects model to pool the HRs. The pooled analysis demonstrated that high Stathmin 1 expression was significantly associated with worse DFS (HR = 2.46, 95% CI: 2.00-3.02, P < 0.001) (Fig. 2B) . The negative effect of high Stathmin 1 expression on DFS was verified in the tumor type subgroup with breast cancer (HR = 2.27, 95% CI: 1.55-3.31, P < 0.001), meningioma (HR = 2.53, 95% CI: 1.94-3.31, P < 0.001), and other cancers (including OSCC, HCC, and gastric adenocarcinoma) (HR = 2.59, 95% CI: 1.43-4.70, P = 0.002) (Fig. 3B) . In addition, differences were significant in other subgroup analyses: Asian patients (HR =2.45; 95% CI: 1.97-3.04; P < 0. 
Meta-analysis of DSS
Six studies that included 2204 patients were included in this part of the meta-analysis. High Stathmin 1 expression yielded a worse DSS (I 2 = 0.0%, P = 0.573, fixed-effects model; HR = 1.98, 95% CI: 1.58-2.47, P < 0.001) (Fig. 2C) . In addition, Stathmin 1 was significantly associated with worse DSS in endometrial cancer (HR = 1.68, 95% CI: 1.18-2.39, P =0.004), urinary bladder cancer (HR = 1.88, 95% CI: 1.27-2.79, P =0.002), and other cancers (included (Fig. 3C) , and other subgroup analyses.
Meta-analysis of PFS/RFS
Considering the similarities between RFS and PFS, we merged them together to conduct this analysis. Three studies that included 421 patients revealed a significant positive association between high Stathmin 1 expression and poor PFS/RFS (I 2 = 0.0%, P = 0.778, fixed-effects model; HR = 2.09, 95% CI: 1.51-2.89, P < 0.001) (Fig. 2D) . Likewise, a similar result was found in different subgroups.
Sensitivity analysis
The sensitivity analysis was conducted to assess the consistency of the above results and performed by sequential omission of each individual study by using the "metaninf" STATA command. There was no significant change in the pooled HRs suggesting that our results were robust (data not shown).
Publication bias
We conducted a publication bias evaluation for the studies in terms of OS and DFS (Fig.  4A and 4B) . The Begg's funnel plot, which provides a visual assessment of the included studies and identifies any overt publication bias, was found to be symmetrical. An Egger's test, which was applied for the formal evaluation of the studies, confirmed the absence of any significant publication bias (P > 0.1). 
Discussion
Stathmin 1 is a microtubule-regulating protein that has an important role in the assembly and disassembly of the mitotic spindle [37] . At the molecular level, Stathmin 1 depolymerizes microtubules by either sequestering free tubulin dimers or directly inducing microtubule-catastrophe [31] . As mentioned before, Stathmin 1 is encoded by the human STMN1 gene, which has 4 serine phosphorylation sites. Phosphorylation at either Ser16 or Ser63 strongly reduces or abolishes the ability of STMN1 to bind to and sequester soluble tubulin [38] . STMN1 Ser16 can be phosphorylated by protein kinase C (PKC), PAK1, or Ca 2+ /calmodulin-dependent kinase II/IV [39, 40] , whereas Ser25 and Ser38 are targeted by mitogen-activated protein kinases (MAPKs) and cyclin-dependent kinases (CDKs) [41] . Overexpression of STMN1 in human cancer not only disrupts normal cell-cycle progression but, more importantly, facilitates polyploidy/aneuploidy of the targeted cells [15] . Stathmin 1 has been implicated in both G1-S and G2-M checkpoint control of cell-cycle progression by influencing the dynamics of microtubule formation and progression of the cell cycle [30] . Kang et al. [42] found that aberrant p53 immunoreactivity was associated with higher STMN1 expression in gastric adenocarcinoma, suggesting that overexpression of STMN1 might be partially due to inactivation of tumor-suppressor gene p53. Batsaikhan et al. [29] also demonstrated that activation-induced cytidine deaminase (AID) could be one of the activators of Stathmin 1 protein expression in gastric adenocarcinoma. P27 and STMN1 correlation was related either directly or by some other pathway. Matsumoto et al. [43] reported that aberrant AID reduces the copy number of CDKs inhibitors such as CDKN2A and CDKN2B, which are tumor suppressive genes and negatively controlled CDKs. AID could be an activator of the STMN1 protein via the AID/CDKN2A/CDKs/STMN1 pathway.
Recently, it was reported that high expression of Stathmin 1 was associated with poor tumor differentiation, large tumor size, advanced N stage, TNM clinical classification, tumor invasion, and distant metastasis in various human malignancies. In addition, it also demonstrated that inhibition of STMN1 expression can enhance the sensitivity of antimicrotubule chemotherapy drugs. Paclitaxel and vinblastine are the most effective chemotherapeutic agents against various cancers. Paclitaxel is a common cytotoxic agent that accelerates microtubule assembly from tubulin and blocks microtubule depolymerization, which leads to cell mitosis stagnation in the G2/M phase, and ultimately apoptosis. Vinblastine affects micro-tubule protein polymerization and stops mitosis. Although the two mechanisms of drug action are different, they both affect the dynamic balance of microtubules. Alli et al. [9] reported that overexpression of Stathmin 1 has been shown to decrease polymerization Meanwhile, a previous study reported that there was an increased STMN1 expression in the resistant A549 cell line [44] , and the expression level of STMN1 was negatively correlated with the efficacy of vinorelbine plus cisplatin/carboplatin therapy in late NSCLC [45] . In addition, Rosell et al. [46] found that STMN1 levels could influence the time to progression of vinorelbine/cisplatin-treated patients. In addition, similar outcomes are also found in patients who treated with vinblastine [26] . It was speculated that STMN1 is critical in the anti-paclitaxel mechanism that blocks microtubule polymerization and reduces its binding to paclitaxel. It was also reported that the transcription factor forkhead box protein M1 (FOXM1) mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin 1 [47] . Moreover, Stathmin 1 has stronger potential as a therapeutic target [10] .
Our study provides a systematic analysis of the role of Stathmin 1 expression as a prognostic factor for solid tumors. We identified that high Stathmin 1 expression was associated with shorter OS, DFS, DSS and PFS/RFS, regardless of tumor type, ethnicity, method used to calculate HRs, detected method, and analysis type, except for HRs estimated indirectly by data extrapolated (P = 0.083), as well as analysis type not reported (P = 0.083). Actually, these were the same 2 studies analyzed in different subgroups. Considering the lower sample size of the only subgroup with different results (140 patients), we can ignore this inconsistent result to some extent.
However, this meta-analysis has several limitations. First, although 23 articles from 26 studies were included in this meta-analysis, the sample size (5335 patients) was relatively small. Second, we only considered studies that calculated, or allowed for the calculation of, HRs and 95% CIs. Other studies that provided odds ratios and relative risk estimates for survival were excluded. In addition, several HRs were calculated based on data extracted from the survival curve, bringing minor deviations. Third, due to the lack of a unified cutoff value in Stathmin 1 expression, different cut-off values were used in those studies. The inaccurate cut-off values may affect the availability of Stathmin 1 as a predictive biomarker in cancer prognosis. In view of this situation, a unified measuring method and cut-off value needs to be established. Fourth, although meta-analysis is now a widely used technique for summarizing evidence from multiple studies, it has its own limitations. All meta-analyses are affected by the quality of the included studies, and by the possibility of publication bias. Finally, owing to the lack of sufficient data, we could not explore the association between Stathmin 1 and other clinical parameters.
Conclusion
This meta-analysis demonstrated that high Stathmin 1 expression is associated with poor prognosis among study patients with solid tumors. Stathmin 1could be used to substantially improve prognosis estimation and treatment decision-making. However, due to the limitation of the present analysis, this conclusion should be regarded cautiously. There is a need for further studies designed adequately with multicenter and larger sample size study designs to confirm our findings, as well as to explore more effective therapeutic strategies.
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